EP0339071A1 - IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS - Google Patents

IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS

Info

Publication number
EP0339071A1
EP0339071A1 EP88909620A EP88909620A EP0339071A1 EP 0339071 A1 EP0339071 A1 EP 0339071A1 EP 88909620 A EP88909620 A EP 88909620A EP 88909620 A EP88909620 A EP 88909620A EP 0339071 A1 EP0339071 A1 EP 0339071A1
Authority
EP
European Patent Office
Prior art keywords
treatment
compound
formula
pyridine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88909620A
Other languages
German (de)
French (fr)
Inventor
Ingemar Starke
Björn Wallmark
Kalervo Väänänen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassle AB filed Critical Hassle AB
Publication of EP0339071A1 publication Critical patent/EP0339071A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Imidazo(1,2-a)(pyridazines or pyrazines) for treatment of diseases related to bone loss.
  • the present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
  • bone formation which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism
  • bone loss which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone
  • osteoporosis can be mentioned, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
  • osteoporosis bone formation as well as bone resorption are disturbed, resulting in decreased bone mass. Osteoporosis predominantly affects the elderly, but also other groups such as postmenopausal women, where an estrogen deficit is believed to be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25 % of osteoporotic females belong to what is called “rapid bone losers" and at least in those patients the bone resorption rate is probably increased. Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H, : The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B:764, 1964).
  • osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures.
  • in Finland it has been estimated that about 10 % of all surgical hospital beds are used for the treatment of osteoporosis related fractures (Luthje, P.: Reisiluunkaulan ja trokantterin murtumapotilaiden hoito ja ennuste seka hiodon kustannukset. Thesis. Helsinki 1983).
  • the present methods for the treatment of osteoporosis include exercise; administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk.
  • Calcitonin a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis. None of these methods of treating osteoporosis results in increase of the bone mass.
  • malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prostate cancer which are both one of the most common malignant tumors.
  • Hypercalcemia is due to both systemic and local factors.
  • Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K., Fujii, Y. Kachivehi, T., Kasono, K., Shizume, K.: Production of interleukin 1 alpha (IL-1 ⁇ )-like activity and colony stimulating activity by clonal squanous cell carcinomas derived from patients with hypercalcemia and leucocytosis.
  • IL-1 ⁇ interleukin 1 alpha
  • Pacret's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated local osteoclastic bone destruction. The incidence of osteitis deformans is very low in Scandinavian countries. In England it has been estimated to be present in 3-4 % of population on the basis of autopsy studies (Anderson's Textbook of Pathology 1986). It is very rare in patients under 40 years. Calcitonin and diphosphonates are also used in the treatment of Paget's disease.
  • Arylalkoxy-, arylalkylamino- and arylalkylthio-substituted imidazo (1,2-a)pyridines and imidazo (1,2-a)pyrazines are known in the art, e.g. EP-Al-0068378 and EP-A1-0033094, as are methods for using these compound to reduce gastric acid secretion.
  • compounds of the general formula I as well as pharmaceutically acceptable salts thereof are effective as inhibitors of basal and stimulated bone resorption and are useful as medicals for the treatment of diseases related to bone loss and increased bone resorption, such as osteoporosis, Pagefs disease of bone, hyperparathyroidism, both primary and secondary, malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia, immobilization-induced osteoporosis, parodontal diseases and prostetic and implant- related bone losses.
  • diseases related to bone loss and increased bone resorption such as osteoporosis, Pagefs disease of bone, hyperparathyroidism, both primary and secondary, malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia, immobilization-induced osteoporosis, parodontal diseases and prostetic and implant- related bone losses.
  • the compounds to be used according to th e i nventi on are of the fol lowing formul a I :
  • A is a nonaromatic 5- or 6-membered ring containing O or 1 heteroatom selected from nitrogen, sulfur and oxygen;
  • R x , B y , R z and R u are H, R 9 or R 10 ;
  • R 9 represents H, loweralkyl, halogen, OH, CF 3 or loweralkoxy
  • R 10 is -Z-T-Ar wherein Z represents -O-, -NH-, -SO m - or a single bond; T represents a straight- or branched chain loweralkylene group; when Z is a single bond, T also represents an ethenylene or a propenylene group wherein the unsaturated carbon is at the single bond; when Z is -O-, T also represent an allylene group wherein the saturated carbon is at the oxygen;
  • n zero, one or two
  • n zero, one or two
  • R 4 and R 5 each independently represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl, Ar, or, when taken together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered cyclic amino group;
  • R 1 represents Ar, loweralkyl, NR 4 R 5 , B-NR 4 R 5 or Ar-loweralkyl;
  • R 6 represents H, C 1 - to C 12 -alkyl, Ar or Ar-loweralkyl
  • R 7 represents H or loweralkyl
  • R 8 represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl or Ar;
  • salts thereof especially acid addition salts such as hydrochloride and hydrobromide salts,
  • R x is R 9 and R Y is H when G is the group
  • halogen includes fluoro, chloro, bromo and iodo, with fluoro and chloro being preferred;
  • lower when applied to alkyl groups, means straight and branched chain alkyl groups having up to six carbon atoms such as methyl, ethyl, propyl, butyl, t-butyl, isopropyl, neopentyl, dimethylbutyl etc., whereby methyl and ethyl are preferred;
  • pyridyl includes the 2-, 3- and 4-isomers and their halogen- or loweralkyl-substituted analogues;
  • thienyl and “furanyl” include the 2- and 3-isomers and their halogen- and loweralkylsubstituted analogues;
  • imidazolyl included the 2- and 4-isomers and their halogen- and loweralkyl-substituted analogues
  • the loweralkylene group represented by T preferably has 1-6, especially 1-3 carbon atoms as in methylene, ethylene and propylene,
  • Suitable “loweralkenyl” may be the ones having 2 to 6 carbon atoms and may include vinyl, allyl, isopropenyl, 1 (or 2 or 3)-butenyl or 1 (or 2 or 3 or 4)-pentenyl.
  • Suitable “loweralkadienyl” may be the ones having 3 to 6 carbon atoms and may include 1,2-propadienyl, 1,2-butadienyl, 1,3-butadienyl, 2,3-pentadienyl or 1,4-pentadienyl.
  • loweralkenyloxy(lower)alkyl suitable examples may include vinyloxymethyl, allyloxymethyl and 1-allyloxyethyl.
  • loweralkynyloxy(lower)alkyl suitable examples may include ethynyloxymethyl, 2-propynyloxymethyl, 2-(2-propynyloxy)ethyl and 1-(2-butynyloxy)propyl.
  • the invention relates to
  • a preferred group of compounds within the general formula I for use according to the present invention is that wherein G is the group
  • Example 1 The compound 8-benzyloxy-3-cyanomethyl-2-methyl-imidazo- (1,2-a)pyridine (Example 1), 8-benzyloxy-3-hydroxylmethyl- 2-methyl-imidazo(1,2-a)pyridine (Example 2) and Example 3 (mentioned above) were tested. As can be seen from Table 1 the compound was found to significantly inhibit both basal bone resorption and PTH-induced bone resportion.
  • the compounds of the formula I are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration.
  • the pharmaceutical formulation contains a compound of the formula I in combination with a pharmaceutically acceptable carrier.
  • the carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule.
  • These pharmaceutical preparations are a further object of the invention.
  • the amount of active compounds is between 0.1-95 % by weight of the preparation, between 0.2-20 % by weight in preparations for parenteral use and between 1 and 50 % by weight in preparations for oral administration.
  • the typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for the treatment of diseases related to loss of bone mass such as osteoporosis, Paget's disease of bone, hy­ perparathyroidism, malignant neoplasms causing hypercalcinemia, parodontal diseases and implant-related bone loss comprising administration to a patient suffering thereform an amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Description

Imidazo(1,2-a)(pyridazines or pyrazines) for treatment of diseases related to bone loss.
Field of the Invention
The present invention is related to a novel method for the treatment of several bone affecting diseases, especially osteoporosis, which are characterized by loss of bone mass.
Background of the Invention
The balance in normal subjects between on the one hand bone formation, which is associated with the number and activity of osteoblasts, that is cells associated with the production of bone in the organism, and on the other hand bone loss, which is associated with the number and activity of osteoclasts, that is cells associated with the absorption and removal of bone, is disturbed in several bone affecting diseases. At the present time there is no good treatment for any of these diseases, among which can be mentioned osteoporosis, Paget's disease of bone, hyperparathyroidism and related disorders, and several malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia.
Worldwide the most urgent need is for the treatment of osteoporosis and tumor associated hypercalcemia. In some areas, e.g. in England and in some other parts of Europe there is also high incidence of Paget's disease of bone.
In osteoporosis bone formation as well as bone resorption are disturbed, resulting in decreased bone mass. Osteoporosis predominantly affects the elderly, but also other groups such as postmenopausal women, where an estrogen deficit is believed to be a significant etiological factor, and immobilized patients. At this point it is not possible to clear up the whole picture of the disease mechanism and estimate which is the primary cause of osteoporosis. However, about 25 % of osteoporotic females belong to what is called "rapid bone losers" and at least in those patients the bone resorption rate is probably increased. Landry and Fleisch showed in immobilization induced osteoporosis that bone resorption rate was accelerated, (Landry, M. and Fleisch, H, : The influence of immobilization on bone formation as evaluated the incorporation of tetracyclines. J. Bone Joint Surg. 46B:764, 1964).
The clinical manifestations of osteoporosis comprise fractures, especially hip fractures, but also vertebral fractures and fractures of the proximal radius, and complication of such fractures. In Finland it has been estimated that about 10 % of all surgical hospital beds are used for the treatment of osteoporosis related fractures (Luthje, P.: Reisiluunkaulan ja trokantterin murtumapotilaiden hoito ja ennuste seka hiodon kustannukset. Thesis. Helsinki 1983).
The present methods for the treatment of osteoporosis include exercise; administration of estrogen, especially for postmenopausal women; and consumption of calcium or calcium containing material such as milk. Calcitonin, a hormone associated with calcium metabolism, has also been used in the treatment of osteoporosis. None of these methods of treating osteoporosis results in increase of the bone mass.
Several malignant tumors are known to be associated by hypercalcemia which is due to increased osteoclastic activity. This is a common complication for instance in the case of breast cancer and prostate cancer which are both one of the most common malignant tumors. Hypercalcemia is due to both systemic and local factors. Some malignant cells are known to secrete agents which stimulate bone resorption (Sato, K., Fujii, Y. Kachivehi, T., Kasono, K., Shizume, K.: Production of interleukin 1 alpha (IL-1α)-like activity and colony stimulating activity by clonal squanous cell carcinomas derived from patients with hypercalcemia and leucocytosis. In: Calcium Regulation and Bone Metabolism Vol. 9 (eds. D.V. Cohu, T.J. Martin, P.J. Meunier), 1986). In malignant hypercalcemia calcitonin and diphcsphonate treatment has been used.
Pacret's disease (or osteitis deformans) of bone is a disease of unknown etiology where bone resorption and remodelling are increased leading sometimes even to the fractures of affected bone. Bone pain is the main indication of treatment in these patients. In these patients there is highly elevated local osteoclastic bone destruction. The incidence of osteitis deformans is very low in Scandinavian countries. In England it has been estimated to be present in 3-4 % of population on the basis of autopsy studies (Anderson's Textbook of Pathology 1986). It is very rare in patients under 40 years. Calcitonin and diphosphonates are also used in the treatment of Paget's disease.
Other disease states for the treatment of which antagonists to osteoclastic activity might be useful, are parodontal diseases and prostetic and implant bone losses.
It is an object of the present invention to provide compounds which by affecting the balance between osteoblast and osteoclast activity can be useful for the prophylactic and therapeutic treatment of diseases as indicated above which are associated with bone loss. It is believed that the use of these compounds will also ultimately result in an increase of the bone mass. Prior art
Arylalkoxy-, arylalkylamino- and arylalkylthio-substituted imidazo (1,2-a)pyridines and imidazo (1,2-a)pyrazines are known in the art, e.g. EP-Al-0068378 and EP-A1-0033094, as are methods for using these compound to reduce gastric acid secretion.
Outline of the present invention - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
According to the present invention it has been found that compounds of the general formula I as well as pharmaceutically acceptable salts thereof are effective as inhibitors of basal and stimulated bone resorption and are useful as medicals for the treatment of diseases related to bone loss and increased bone resorption, such as osteoporosis, Pagefs disease of bone, hyperparathyroidism, both primary and secondary, malignant neoplasms where tumor cells are producing osteoclast-activating factors and cause hypercalcemia, immobilization-induced osteoporosis, parodontal diseases and prostetic and implant- related bone losses.
The compounds to be used according to th e i nventi on are of the fol lowing formul a I :
wherein G is
whereby the carbon atom of the group is connected to the 2-position of the imidazo-moiety, thus forming an imidazo (1,2-a)pyrazine nucleus, A is a nonaromatic 5- or 6-membered ring containing O or 1 heteroatom selected from nitrogen, sulfur and oxygen; R2 represents H, lower alkyl, CF3, B-CF3, B-Ar, Ar, B-halogen, BOR8, B-SOm-loweralkyl, BOC(=0)R1, B-NR4R5, COOR6, C(=0)-NR4R5, B-CN or NR4R5;
represents H, loweralkyl, loweralkenyl, loweralkynyl, loweralkadienyl, loweralkenyloxy (lower) alkyl, loweralkynyloxy(lower)alkyl, carboxy(lower)alkynyloxy(lower)- alkyl, protected carboxy(lower)alkynyloxy(lower)alkyl, BCN, BOR8, BOC(=0)-R1, B-NR4R5, B-C (=S) -NR4R5, B-C (=0) NR4R5, B-NO2, B-halogen, B-NC, NO or NR4R5;
Rx, By, Rz and Ru are H, R9 or R10;
R9 represents H, loweralkyl, halogen, OH, CF3 or loweralkoxy;
R10 is -Z-T-Ar wherein Z represents -O-, -NH-, -SOm- or a single bond; T represents a straight- or branched chain loweralkylene group; when Z is a single bond, T also represents an ethenylene or a propenylene group wherein the unsaturated carbon is at the single bond; when Z is -O-, T also represent an allylene group wherein the saturated carbon is at the oxygen;
Ar represent phenyl, pyridyl, thienyl, furanyl, imidazolyl or X'-, Y'- and/or Z'-substituted phenyl wherein each of X', Y' and Z ' independently is hydrogen, halogen, loweralkyl, loweralkoxy, CN, CF3, OH, NO2, -NR4R5, -COOR6, -C(=0)NR4R5, -NR7C(=0)R1, -NR7SOmR1 or -SOmR1; B is a straight or branched chain loweralkylene group;
n represents zero, one or two;
m represents zero, one or two;
R4 and R5 each independently represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl, Ar, or, when taken together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered cyclic amino group;
R1 represents Ar, loweralkyl, NR4R5, B-NR4R5 or Ar-loweralkyl;
R6 represents H, C1- to C12-alkyl, Ar or Ar-loweralkyl;
R7 represents H or loweralkyl; and
R8 represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl or Ar;
as well as pharmaceutically acceptable salts thereof, especially acid addition salts such as hydrochloride and hydrobromide salts,
provided that
(a) one, and only one, of the groups Rx, Ry, Rz and Ru is R10
(b) not more than one of the groups Rx, Ry, Rz and Ru is R9
(c) Rx is R9 and RY is H when G is the group
As used herein, the term "halogen" includes fluoro, chloro, bromo and iodo, with fluoro and chloro being preferred; the term "lower", when applied to alkyl groups, means straight and branched chain alkyl groups having up to six carbon atoms such as methyl, ethyl, propyl, butyl, t-butyl, isopropyl, neopentyl, dimethylbutyl etc., whereby methyl and ethyl are preferred; the term "pyridyl" includes the 2-, 3- and 4-isomers and their halogen- or loweralkyl-substituted analogues; the terms "thienyl" and "furanyl" include the 2- and 3-isomers and their halogen- and loweralkylsubstituted analogues; the term "imidazolyl" included the 2- and 4-isomers and their halogen- and loweralkyl-substituted analogues.
The loweralkylene group represented by T preferably has 1-6, especially 1-3 carbon atoms as in methylene, ethylene and propylene,
Suitable "loweralkenyl" may be the ones having 2 to 6 carbon atoms and may include vinyl, allyl, isopropenyl, 1 (or 2 or 3)-butenyl or 1 (or 2 or 3 or 4)-pentenyl.
Suitable "loweralkadienyl" may be the ones having 3 to 6 carbon atoms and may include 1,2-propadienyl, 1,2-butadienyl, 1,3-butadienyl, 2,3-pentadienyl or 1,4-pentadienyl. In the term "loweralkenyloxy(lower)alkyl", suitable examples may include vinyloxymethyl, allyloxymethyl and 1-allyloxyethyl.
In the term "loweralkynyloxy(lower)alkyl", suitable examples may include ethynyloxymethyl, 2-propynyloxymethyl, 2-(2-propynyloxy)ethyl and 1-(2-butynyloxy)propyl.
Accordingly, the invention relates to
- a method for the prophylactic and therapeutic treatment of each of the ailments above by administering to a host in need thereof of an effective amount of a compound of the formula I
- a pharmaceutical preparation for use in the prophylactic and therapeutic treatment of each of the ailments above comprising a compound of the formula I as active ingredient
- a compound of the formula I for use in the manufacture of a medicament for the prophylactic and therapeutic treatment of each of the ailments above
- a method for improving the healing rate of bone fractures by administering to a host in need thereof of an effective amount of a compound of the formula I
The illustrative examples given above for the various radicals in the formula I will be applicable to the different radicals depending on the number of carbon atoms prescribed for each radical. The following compounds are typical representatives of the preferred compounds of this invention:
2-Methyl-8-(2,4,6-trimethylbenzyloxy)imidazo(1,2-a)pyridine;
8-(3,4-Dichlorobenzyloxy)-2-methyl-imidazo(1,2-a)pyridine;
8-(2-Fluorobenzyloxy)-2-methyl-imidazo(1,2-a)pyridine;
8-(4-Fluorobenzyloxy)-2-methyl-imidazo(1,2-a)pyridine; 2-Methyl-8-(2-phenylethyl)-imidazo(1,2-a)pyridine;
8-(4-Chlorobenzyloxy)-2-methyl-imidazo(1,2-a)pyridine;
8-Benzylsulfinyl-3-cyanomethyl-2-methyl-imidazo(1,2-a)pyridine;
3-Cyanomethyl-2-methyl-8-(2-thienyl-methoxy)-imidazo(1,2-a) pyridine;
3-Cyanomethyl-2-methyl-8-(2-pyridyl-methoxy)-imidazo(1,2-a) pyridine;
3-Cyanomethyl-2-methyl-8-(4-trifluoromethylbenzyloxy)-imidazo (1,2-a)pyridine;
3-Cyanomethyl-8- (3, 4-dichlorobenzyloxy) -2-methyl-imidazo (1, 2-a) pyridine;
3-Cyanomethyl-8- (4-methoxybenzyloxy) -2-methyl-imidazo (1, 2-a) pyridine;
8- (4-t-butylbenzyloxy) -3-cyanomethyl-2-methyl-imidazo (1 , 2-a) pyridine;
8-Benzylthio-3-cyanomethyl-2-methyl-imidazo (1, 2-a) pyridine;
3-Cyanomethyl-2-methyl-8- (3-trifluoromethylbenzyloxy) imidazo (1, 2-a) pyridine;
8-(4-chlorobenzyloxy)-3-cyanomethyl-2-methyl-imidazo (1,2-a)pyridine;
8-Benzyloxy-2-methyl-imidazo(1,2-a)pyridine-3-methylpivaloate; 8-(3,4-Dichlorobenzyloxy)-3-hydroxymethyl-2-mezhyl-imidazo (1,2-a)pyridine;
8-Benzyloxy-2-methyl-imidazo (1, 2-a) pyridine-3- (2-butanonitrile
8- (4-Chlorobenzyloxy) -3-hydroxymethyl-2-methyl-imidazo (1, 2-a) pyridine;
8-Benzyloxy -2-ethyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-2-methylsulfinylmethyl-imidazo (1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-2-methylthiomethyl-imidazo (1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-imidazo(1,2-a)pyridine-2-methyl-N,N-dimethylglycinate;
8-(4-Cyanobenzyloxy)-3-cyanomethyl-2-methyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-2-cyanomethyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-2-methyl-imidazo(1,2-a)pyridine-3-methylacetate;
8-Benzyloxy-3-cyanomethyl-2-hydroxymethyl-imidazo(1,2-a)pyridine;
3-Hydroxymethyl-2-methyl-8-(2-phenylethoxy)-imidazo(1,2-a)pyridine;
8-Benzyloxy-2, 3-dimethyl-imidazo (1, 2-a) pyridine;
3-Cyanomethyl-2-methyl-8- (2-phenylethoxy) -imidazo (1, 2-a)pyridine;
3-Cyanomethyl-2-methyl-8- (1-phenylethoxy) -imidazo (1, 2-a)pyridine;
3-Cyanomethyl-2-methyl-8-(2-phenylethyl)-imidazo(1,2-a)pyridine;
8-Benzyloxy-2-methyl-imidazo (1, 2-a) pyridine-3-thioacetamide;
3-Hydroxymethyl-2-methyl-8- (2-phenylethyl) -imidazo (1, 2-a)pyridine; 3-Cyanomethyl-2-methyl- 8- (3-phenylpropoxy) -imidazo (1 , 2-a) pyridine;
8-Benzyloxy-3-cyanomethyl-2-isopropyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-2-ethyl-imidazo(1,2-a)pyridine;
8-Benzylamino-2,3-dimethyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-3-cyanomethyl-2-methyl-imidazo(1,2-a)pyridine;
8-Benzyloxy-3-hydroxymethyl-2-methyl-imidazo(1,2-a)pyridine;
3-Hydroxymethyl-8-(2-fluorobenzyloxy)-2-methyl-imidazo (1,2-a)pyridine;
8- ( 4-t-Butylbenzyloxy) -3-hydroxymethyl-2-methyl-imidazo (1 , 2-a) pyridine;
3-Cyanomethyl-8-(2-fluorobenzyloxy-2-methyl-imidazo(1,2-a)pyridine;
3-Cyanomethyl-8-(4-fluorobenzyloxy-2-methyl-imidazo(1,2-a)pyridine;
3-Cyanomethyl-2-methyl-8-(2,4,6-trimethylbenzyloxy)-imidazo (1,2-a)pyridine;
8-Benzylamin-3-cyanomethyl-2-methyl-imidazo(1,2-a)pyridine;
3-Cyanomethyl-2-methyl-8-(3-thienyl-metoxy)-imidazo(1,2-a)pyridine;
2,3-Dimethyl-8-[1-E-(3-phenylpropenyl)]-imidazo(1,2-a)pyridine;
2,3-Dimethyl-8-[(2-phenyl)-ethenyl]imidazo(1,2-a)pyridine;
3-Cyanomethyl-2-methyl-8-[E-(2-phenyl-1-ethenyl)]imidazo (1,2-a)pyridine;
3-Cyanomethyl-2-methyl-8-[E-1-(3-phenyl-propen-1-yl)]imidazo (1,2-a)pyridine;
3-Cyanomethyl-2-methyl-6-(2-phenylethyl)imidazo(1,2-a)pyridine;
3-Amino-8-benzyloxy-2-ethyl-imidazo(1,2-a)pyridine; 3-Amino-8-benzyloxy-2,7-dimethyl-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-8-(2-phenylethyl)-imidazo(1 ,2-a)pyridine; 3-Amino-2-methyl-8-(3-thienylmethoxy)-imidazo(1,2-a) pyridine;
3-Dimethylamino-2-methyl-8-phenylmethoxy-imidazo(1,2-a)pyridine;
3-Amino-8-benzyloxy-2,6-dimethyl-imidazo(1,2-a)pyridine; 8-Benzyloxy-3-ethylamino-2-methyl-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-8-[(3-thienylmethyl)-amino]-imidazo (1,2-a)pyridine;
3-Amino-2-methyl-8-[Z(2-phenylethenyl)]-imidazo(1,2-a)pyridine;
3-Amino-8-(4-chlorophenylmethoxy)-2-methyl-imidazo(1,2-a)pyridine;
3-Amino-2-methyl-7-(2-phenylethyl)-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-8-(2-thienylmethoxy)-imidazo(1,2-a) pyridine;
Trans-3-Amino-2,6-dimethyl-8-(2-phenylethenyl)-imidazo (1,2-a)pyridine;
3-Amino-8-(2-fluorophenylmethoxy)-2-methyl-imidazo(1,2-a)pyridine;
3-Amino-8-(4-fluorophenylmethoxy)-2-methyl-imidazo(1,2-a)pyridine;
3-Amino-8-benzylamino-2-methyl-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-8-(2-phenylethenyl)-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-6-(2-phenylethyl)-imidazo(1,2-a)pyridine; 3-Amino-2-methyl-8-[E-1-(32-phenylpropen-1-yl)]-imidazo (1,2-a)pyridine;
3-Ethylamino-2-methyl-8-(2-phenylethyl)-imidazo(1,2-a)pyridine;
3-Amino-2,7-dimethyl-8-(2-phenylethyl)-imidazo(1,2-a)pyridine; 8-Benzyloxy-3-isocyanomethyl-2-methyl-imidazo(1,2-a) pyridine;
8-benzyloxy-3-cyanomethyl-2-methyl-imidazo(1,2-a) pyrazine;
3-amino-8-benzyloxy-2-methyl-imidazo(1,2-a)pyrazine;
8-benzyloxy-3-ethylamino-2-methyl-imidazo(1,2-a) pyridine;
8-benzyloxy-3-allyl-2-methylimidazo(1,2-a)pyridine;
8-benzyloxy-3-(2-propynyl)-2-methylimidazo(1,2-a) pyridine;
8-(2-phenylethoxy)-3-(2-propynyl)-2-methylimidazo(1,2-a)pyridine;
8-(2-methylbenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine:
8-(2-ethylbenzyloxy)-3-(2-propynyl)-2-methylimidazo(1,2-a)pyridine;
8-(2-isopropylbenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-chlorobenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(3-chlorobenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(4-chlorobenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-bromobenzyloxy)-3-(2-propynyl)-2-methylimidazo(1,2-a)pyridine;
8-(2-fluorobenzyloxy)-3-(2-propynyl)-2-methylimidazo(1,2-a)pyridine
8-(2,6-dimethylbenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine; 8-(2,6-dichlorobenzyloxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-benzyloxy-3-(2-propynyloxymethyl)-2-phenylimidazo(1,2-a) pyridine;
8-(2-methylbenzylamino)-3-(2-propynyloxymethyl-2- methylimidazo(1,2-a)pyridine hydrochloride; 8-(2-chlorobenzylamino)-3-(2-propynyloxymethyl)-2-methylimidazo(1,2-a)pyridine hydrochloride; 8-benzyloxy-3-allyloxymethyl-2-methylimidazo(1,2-a) pyridine;
8-benzyloxy-3-(3-carboxy-2-propynyloxymethyl)-2- methylimidazo(1,2-a)pyridine;
8-benzyloxy-3-(3-ethoxycarbonyl-2-propynyloxymethyl)-2- methylimidazo(1,2-a)pyridine;
8-(2-naphthylmethoxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(1-naphthylmethoxy)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-methylbenzylamino)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-chlorobenzylamino)-3-(2-propynyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-methylbenzyloxy)-3-(1,2-propadienyl)-2-methylimidazo (1,2-a)pyridine;
8-benzyloxy-3-(2-propynyloxymethyl)-2-methylimidazo(1,2-a) pyridine hydrochloride;
8-benzyloxy-3-(2-propynyloxymethyl)-2-methylimidazo(1,2-a) pyridine
8-(1-phenylethoxy)-3-(2-propynyloxymethyl)-2-methylimidazo (1,2-a)pyridine; 8-(2-methylbenzyloxy)-3-(2-propynyloxymethyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-chlorobenzyloxy)-3-(2-propynyloxymethyl)-2-methylimidazo (1,2-a)pyridine;
8-(3-chlorobenzyloxy)-3-(2-propynyloxymethyl)-2-methylimidazo (1,2-a)pyridine;
8-(4-chlorobenzyloxy)-3-(2-propynyloxymethyl)-2-methylimidazo (1,2-a)pyridine;
8-(2-bromobenzyloxy)-3-(2-propynyloxymethyl)-2-methylimidazo
(1,2-a)pyridine;
8-(2,6-dichlorobenzyloxy)-3-(2-propynyloxymethyl)-2- methylimidazo(1,2-a)pyridine;
8-(3,4-dichlorobenzyloxy)-3-(2-propynyloxymethyl)-2- methylimidazo(1,2-a)pyridine;
8-(2,4-dichlorobenzyloxy)-3-(2-propynyloxymethyl)-2- methylimidazo(1,2-a)pyridine;
8-benzyloxy-3-(2-propynyloxymethyl)imidazo(1,2-a)pyridine.
A preferred group of compounds within the general formula I for use according to the present invention is that wherein G is the group
especially the compounds wherein n is 0. A particulary preferred compound for use according to the present invention is
Pharmacological tests
In order to evaluate the inhibitory effect on bone resorption, and in vitro model, the mouse calvaria explant model (described in Reynolds, J.J. Organ cultures of bone: Studies on the physiology and pathology of bone resorption. In: Organ culture in biomedical research (Bulls M., and Monnichendam M.A. eds) Cambridge University Press, p.p. 355-366, 1976) was used. In this model the effects of the compounds on the basal and the parathyroidhormone (PTH)-induced bone resorption are measured.
Results - - - - - - -
The compound 8-benzyloxy-3-cyanomethyl-2-methyl-imidazo- (1,2-a)pyridine (Example 1), 8-benzyloxy-3-hydroxylmethyl- 2-methyl-imidazo(1,2-a)pyridine (Example 2) and Example 3 (mentioned above) were tested. As can be seen from Table 1 the compound was found to significantly inhibit both basal bone resorption and PTH-induced bone resportion.
Table 1. Effect of Examples, on basal and parathyroid hormone-induced bone resorption in vitro
% release of 45Ca2+
Devitalized preparation (n=6) 7 ± 0.8
Control (=basal) (n=6) 19 ± 4.0
Example 1 10-4mol/l (n=6) 11 ± 0.8 p<0.001
Example 1 10-5mol/l (n=6) 14 ± 2.1 p<0.02
PTH 100 ng/ml (n=6) 28 ± 6.9
PTH + Example 1 10-4mol/l (n=4) 12 ± 1.6 p<0.002
PTH + Example 1 10-5mol/l (n=4) 17 ± 3.3 p<0.02 % release of 45Ca2+
Devitalized preparation (n=5) 6.6 ± 0.5 Control (=basal) (n=5) 26.2 ± 3.2 Example 2 10-4 mol/1 (n=4) 21.0 ± 2.3
Control (=basal) (n=5) 25.7 ± 1.9 Example 3 10-4 mol/1 (n=5) 7.9 ± 0.6
PTH 100 ng/ml (n=5) 34.8 ± 1.1
PTH + Example 2 10-4 mol/1 (n=5) 24.0 ± 2.5
PTH 100 ng/ml (n=5) 26.6 ± 4.1
PTH + Example 3 10-4 mol/1 (n=5) 8.2 ± 0.3
For clinical use the compounds of the formula I are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. The pharmaceutical formulation contains a compound of the formula I in combination with a pharmaceutically acceptable carrier. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1-95 % by weight of the preparation, between 0.2-20 % by weight in preparations for parenteral use and between 1 and 50 % by weight in preparations for oral administration.
The typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.

Claims

What we claim is:
1. A method for the treatment of osteoporosis by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I below, optionally together with a pharmaceutically acceptable carrier:
wherein G is
whereby the carbon atom of the group is connected to the 2-position of the imidazo-moiety, thus forming an imidazo (1,2- )pyrazine nucleus; A is a nonaromatic 5- or 6-membered ring containing 0 or 1 heteroatom selected from nitrogen, sulfur and oxygen;
R2 represents H, lower alkyl, CF3, B-CF3, B-Ar, Ar, B-halogen, BOR8, B-SOm-loweralkyl, BOC(=0)R1, B-NR4R5, COOR6, C(=0)-NR4R5, B-CN or NR4R5;
R3 represents H, loweralkyl, loweralkenyl, loweralkynyl, loweralkadienyl, loweralkenyloxy(lower)alkyl, loweralkynyloxy(lower)alkyl, carboxy(lower)alkynyloxy(lower)- alkyl, protected carboxy(lower)alkynyloxy(lower)alkyl, BCN, BOR8, BOC(=0)-R1, B-NR4R5, B-C (=S) -NR4R5, B-C (=0) NR4R5, B-NO2, B-halogen, B-NC, NO or NR4R5;
Rx, Ry , Rz and Ru are H, R9 or R10;
R9 represents H, loweralkyl halogen, OH, CF3 or loweralkoxy;
R10 is -Z-T-Ar wherein Z represents -O-, -NH-, -SOm- or a single bond; T represents a straight- or branched chain loweralkylene group; when Z is a single bond, T also represents an ethenylene or a propenylene group wherein the unsaturated carbon is at the single bond; when Z is -O-, T also represent an allylene group wherein the saturated carbon is at the oxygen; Ar represent phenyl, pyridyl, thienyl, furanyl, imidazolyl or X'-, Y'- and/or Z'-substituted phenyl wherein each of X', Y' and Z' independently is hydrogen, halogen, loweralkyl, loweralkoxy, CN, CF3, OH, NO2, -NR4R5, -COOR6, -C(=0)NR4R5, -NR7C(=0)R1, -NR7SOmR1 or -SOmR1;
B is a straight or branched chain loweralkylene group;
n represents zero, one or two;
m represents zero, one or two;
R4 and R5 each independently represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl, Ar, or, when taken together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered cyclic amino group;
R1 represents Ar, loweralkyl, N R4 R5, B-N R4R5 or Ar-loweralkyl;
R6 represents H, C1- to C12-alkyl, Ar or Ar-loweralkyl;
R7 represents H or loweralkyl and;
R8 represents H, loweralkyl, loweralkoxyloweralkyl, trifluoromethylloweralkyl, Ar-loweralkyl or Ar;
as well as pharmaceutically acceptable salts thereof, especially acid addition salts such as hydrochloride and hydrobromide salts, provided that
(a) one, and only one, of the groups Rx, Ry, Rz and Ru is R10
(b) not more than one of the groups Rx, Ry, Rz and Ru is R9
(c) Rx is R9 and Ry is H when G is the group
2. A method for the treatment of Paget's disease of bone by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
3. A method for the treatment of primary and secondary hyperparathyroidism by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
4. A method for the treatment of such malignant neoplasms where tumor cells are producing osteoclast-activating factors, by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
5. A method for the treatment of parodontal diseases, by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
6. A method for the treatment of prostetic and implant- related bone loss, by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
7. A method for the treatment of disease connected with increased bone resorption by administering to a host in need of such treatment of a therapeutically effective amount of a compound of the formula I as defined in claim 1, optionally together with a pharmaceutically acceptable carrier.
8. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of osteoporosis.
9. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of Page's disease of bone.
10. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of primary and secondary hyperparathyroidism.
11. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of such malignant neoplasms where tumor cells are producing osteoclast acitvating factors.
12. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of parodontal diseases.
13. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of prostetic and implant-related bone loss.
14. A compound of the formula I as defined in claim 1 for use in the manufacture of a medicament for the treatment of diseases connected with increased bone resorption.
15. A pharmaceutical preparation for use in the treatment of diseases connected with increased bone resorption; osteoporosis; Pagefs disease of bone; primary and secondary hyperparathyroidism; such malignant neoplasms where tumor cells are producing osteoclast-activating factors; such parodontal diseases which are associated with bone loss; or prostetic and implant-related bone loss; and comprising a compound of the formula I as defined in claim 1 as active ingredient.
16. A method for improving the healing rate of bone fractures by administering to a host in need thereof of an effective amount of a compound as defined in claim 1.
17. A compound as defined in claim 1 for use in the manufacture of a medicament for improving the healing rate of bone fractures.
18. A pharmaceutical preparation for use in improving the healing rate of bone fractures, comprising a compound as defined in claim 1 as active ingredient.
EP88909620A 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS Withdrawn EP0339071A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704248A SE8704248D0 (en) 1987-10-30 1987-10-30 MEDICAL USE
SE8704248 1987-10-30

Publications (1)

Publication Number Publication Date
EP0339071A1 true EP0339071A1 (en) 1989-11-02

Family

ID=20370069

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88909620A Withdrawn EP0339071A1 (en) 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS

Country Status (9)

Country Link
EP (1) EP0339071A1 (en)
JP (1) JPH02501929A (en)
KR (1) KR890701587A (en)
AU (1) AU2620388A (en)
DK (1) DK322189A (en)
HU (1) HU203663B (en)
IL (1) IL88205A0 (en)
SE (1) SE8704248D0 (en)
WO (1) WO1989003833A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656101B2 (en) * 1987-07-16 1997-09-24 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング New diazole
US5081253A (en) * 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
US5464843A (en) * 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
WO1996034866A1 (en) * 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
GB9518552D0 (en) * 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
DE102012200349A1 (en) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituted fused pyrimidines and triazines and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
WO2014195333A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
PE20160201A1 (en) 2013-07-10 2016-05-06 Bayer Pharma AG BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USE
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
WO2015140199A1 (en) 2014-03-21 2015-09-24 Bayer Pharma Aktiengesellschaft Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2947372A1 (en) * 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft 6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators
CA2947376A1 (en) * 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases
US20170057958A1 (en) 2014-05-02 2017-03-02 Bayer Pharma Aktiengesellschaft Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
JP2017537922A (en) 2014-12-02 2017-12-21 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted pyrazolo [1,5-a] pyridine and imidazo [1,2-a] pyrazine and uses thereof
JP2017536396A (en) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト Heteroaryl substituted imidazo [1,2-a] pyridines and uses thereof
WO2016124564A1 (en) 2015-02-05 2016-08-11 Bayer Pharma Aktiengesellschaft N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cylase (sgc) for the treatment of cardiovascular diseases
JP2018505885A (en) 2015-02-05 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted pyrazolo [1,5-a] -pyridine-3-carboxamide and uses thereof
WO2018184976A1 (en) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyridinecarboxamides and use of same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4468400A (en) * 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
DE3446778A1 (en) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach NEW IMIDAZO DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
EP0228006A1 (en) * 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8903833A1 *

Also Published As

Publication number Publication date
WO1989003833A1 (en) 1989-05-05
SE8704248D0 (en) 1987-10-30
DK322189D0 (en) 1989-06-28
HUT51138A (en) 1990-04-28
IL88205A0 (en) 1989-06-30
HU203663B (en) 1991-09-30
KR890701587A (en) 1989-12-21
AU2620388A (en) 1989-05-23
JPH02501929A (en) 1990-06-28
DK322189A (en) 1989-06-28

Similar Documents

Publication Publication Date Title
EP0339071A1 (en) IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS
US6596726B1 (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5679683A (en) Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
EP0790997B1 (en) 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
US6720334B2 (en) Urea substituted imidazopyridines
KR100284473B1 (en) Bicyclic-heterocyclic amines with pharmacological activity
KR0162654B1 (en) N-[pyrrolo (2, 3-d) pyrimidin-3yl acryl]-glutamic acid derivatives
US4725601A (en) Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
SI9620103A (en) Pyrrolopyrimidines and processes for the preparation thereof
JP2005538992A (en) Kinase inhibitor
AU2002315006A1 (en) Urea substituted imidazopyridines
HU221741B1 (en) Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor, pharmaceutical compositions containing such compounds and use thereof
US20060035899A1 (en) Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
AU2006264801B2 (en) Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
Su et al. Synthesis and biological activities of 5-deaza analogs of aminopterin and folic acid
BR112020012218A2 (en) compound of general formula and composition
JP2002523415A (en) New compounds
US4897395A (en) Treatment with dialkoxy pyridopyrimidines
US5354773A (en) Use of bafilomycine and derivatives to treat bone diseases
KR20040111324A (en) Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
NZ230098A (en) Compositions containing substituted 2,3-dihydroimidazo-(2,1-a) isoquinolines
WO1989003830A1 (en) 2-pyridinylmethyl (sulfinyl or thio)benzimidazoles for treatment of diseases related to bone loss
US5081253A (en) Imidazo(4,5-c)pyridines as antiosteoporotic agents
PT96069A (en) A method for the preparation of UIDAL IMIDAZO (1,2-A) PYRIDINYLALKYL COMPOUNDS FOR THE TREATMENT OF NEUROTOXIC DANES
AU641445C (en) Bafilomycine macrolides for treatment of bone affecting diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920501